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1. Introduction  
Hemophagocytic syndrome (HPS), also known as hemophagocytic lymphohistiocytosis 
(HLH) encompasses an infrequent group of non-malignant, yet potentially life-threatening 
disorders caused by massive cytokine release from activated lymphocytes and macrophages 
(Filipovich, 2009; Henter et al., 1998, 2007; Janka et al., 1998; Janka, 2009). This multisystem 
inflammatory syndrome is associated with a range of genetic and acquired factors. Hectic 
and persistent fever, cytopenias, hepatitis, jaundice, edema, splenomegaly, neurological 
symptoms and hemophagocytosis in bone marrow (BM), liver or lymph nodes are common 
clinicopathological features of HLH.   
2. Historical background and terminology of HLH 
The first published report on HLH is presumably an observation of hemophagocytosis in 
malignancy (Tschistowitsch & Bykova, 1928). In 1939, Scott and Robb-Smith reported four 
similar cases of adults with an HLH-like picture and proposed to call this condition 
histiocytic medullary reticulosis (HMR) (Scott & Robb-Smith, 1939). The term HMR was 
later succeeded by the disease entity known as malignant histiocytosis (MH) (Rappaport, 
1966). The familial form of HLH (named FHL or FHLH) was first described in a family with 
two affected siblings (Farquhar & Claireaux, 1952). Risdall et al. later reported a series of 19 
patients with active viral infection, whose bone marrow smears disclosed histiocytic 
hyperplasia with prominent hemophagocytosis (Risdall et al., 1979). Of note, 14 of 19 
patients in this study were immunosuppressed and active infection with herpes group 
viruses was documented in 74% (14/19) of patients. They proposed to term this condition 
virus-associated hemophagocytic syndrome (VAHS). Some authors argue that this paper by 
Risdall and colleagues is the first well documented report of acquired (or secondary) HLH 
(sHLH) (Kumakura, 2005). Five years later, Risdall et al. also reported HPS in three patients 
with bacterial sepsis (Risdall et al., 1984). This condition was named bacteria-associated 
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hemophagocytic syndrome (BAHS). To date, sHLH is known to be associated not only with 
viral or bacterial infections, but also with different types of other disseminated infections, 
including fungal or parasitic infections (Janka et al., 1998). Therefore, HLH associated with 
any infection type is collectively called infection-associated hemophagocytic syndrome 
(IAHS) or infection-associated hemophagocytic lymphohistiocytosis (I-HLH) (Kumakura et 
al., 2004).  
The origin of the proliferating cells in MH has been thought to be the precursors of 
histiocytes, but then it has been clarified that the proliferating cells are lymphoma cells 
(Kumakura, 2005). In 1981, a case of T-cell lymphoma resembling MH was reported (Kadin, 
1981). Following this report, many lymphoma cases associated with HPS have been reported 
worldwide (Han et al., 2007; Hasselblom et al., 2004; Ishii et al., 2007; Janka et al., 1998; 
Reiner & Spivak, 1988; Tong et al., 2008). In most of these cases it was proven that the 
proliferating cells were not of histiocytic origin, but that they were lymphoma cells. 
Therefore, the ‘true MH’, which is recognized as a neoplastic disease of immature 
histiocytes, is thought to be very infrequent, and secondary HLH associated with lymphoma 
is called lymphoma-associated hemophagocytic syndrome (LAHS) (Kumakura, 2004). Later, 
it has become clear that other hematological malignancies (e.g. myelodysplastic syndromes, 
acute and chronic leukemias, multiple myeloma) and solid cancers (e.g. thymoma, 
carcinoma, germ cell tumor, hepatocellular carcinoma) can be associated with HLH as well 
(Gupta et al., 2009; Ishii et al., 2007; Janka et al., 1998; Lackner et al., 2008; Machaczka et al., 
2010; Reiner & Spivak, 1988; Shabbir et al., 2010). Thus, HLH associated with any 
malignancy should be collectively called malignancy-associated hemophagocytic syndrome 
(MAHS) or malignancy-associated hemophagocytic lymphohistiocytosis (M-HLH). 
In 1991, Wong reported six patients with active systemic lupus erythematosus (SLE) who 
demonstrated reactive bone marrow hemophagocytosis (Wong et al., 1991). Since there was 
no evidence of an underlying infection, hemophagocytosis was thought to be solely 
associated with the activity of SLE, and the authors proposed to name this condition acute 
lupus hemophagocytic syndrome (ALHS). Shortly thereafter, Kumakura et al. reported 
cases of secondary HLH associated with autoimmune diseases other than SLE, and 
postulated to consider a new disease entity autoimmune-associated hemophagocytic 
syndrome (AAHS) (Kumakura et al., 1995, 1997). Albert et al. were the first to use the term 
‘macrophage activation syndrome’ (MAS) in a description of the disorder (Albert et al., 
1992). Shortly after, Stephan et al. used the term MAS in their description of 4 children 
suffering from chronic rheumatic disease characterized by a pro-inflammatory milieu 
(Stephan et al., 1993). MAS has been often reported in cases of systemic juvenile idiopathic 
arthritis (sJIA), but is also a known complication of adult onset Still’s disease (AOSD), 
systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjögren’s syndrome, 
dermatomyositis, Kawasaki disease, mixed connective tissue disease and systemic sclerosis 
(Carvalheiras et al., 2010; Davi et al., 2011; Fukaya et al., 2008; Grom & Mellins, 2010; 
Hendricks et al., 2010; Kumakura et al., 2004; Parodi et al., 2009; Sawhney et al., 2001; 
Simonini et al., 2010; Titze et al., 2009; Tristano, 2008). 
Recognition in recent years that MAS belongs to the class of sHLH has led to a proposal to 
rename it according to the contemporary classification of histiocytic disorders (Ramanan & 
Baildam, 2002). Some authors have suggested that the term MAS be dropped in favor of 
reactive HLH to reflect this similarity and to better familiarize pediatric rheumatologists 
with treatment options, particularly in patients not responding to frontline therapy (Grom 
2003). Nevertheless, use of the term MAS still remains prevalent in the rheumatology 
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literature, whereas syndromes described in the hematology and infectious disease literature 
often describe a similar phenomenon as secondary HLH (Deane et al., 2010). Some authors 
suggest that the terms MAS and HLH are interchangeable (Behrens, 2008; Behrens et al., 
2008; Emmenegger et al., 2005; Ramanan & Baildam, 2002), whereas others describe MAS as 
a distinct subset of sHLH (Arceci, 2008; Janka, 2007, 2009), and still others highlight the 
heterogeneity of disorders described by both terms and call for revised terminology based 
more precisely on pathophysiology (Grom et al., 2003; Grom & Mellins, 2010). 
3. Classification of HLH 
According to the aforementioned historical background and current progress in 
understanding of its pathophysiology, HLH is generally divided into two distinct forms: an 
inherited, familial form and an acquired, secondary form (Arceci 2008; Janka, 2009; Henter 
et al., 2007). FHL has an autosomal recessive inheritance pattern, and usually arises in 
infants (80% cases), however in rare cases it can also occur in adults (Gupta & Weitzman, 
2010; Henter et al., 1991b, 1998, 2007; Nagafuji et al., 2007). Acquired HLH can develop at 
any age, from childhood to the elderly, as a result of intensive immunological activation due 
to severe infections, autoimmune inflammatory disorders or malignancies (Janka, 2009; 
Henter et al., 2007). HLH as a serious complication of autoimmune diseases is commonly 
called macrophage activation syndrome or autoimmune-associated hemophagocytic 
syndrome. Macrophage activation syndrome as a severe complication of the systemic form 
of juvenile idiopathic arthritis (sJIA) is a prototype of AAHS. Nowadays MAS is considered 
a special form of acquired HLH by most rheumatologists. However, it should be 
emphasized that in the literature dealing with HLH in adults, MAS is sometimes used 
synonymously with acquired HLH regardless of its cause (Janka, 2009). The contemporary 
classification of HLH is presented in Table 1. 
4. Epidemiology of HLH 
Until recently, it was widely believed that FHL because of genetic causes arose during 
infancy and early childhood. In a retrospective Swedish study the incidence of FHL was 
estimated to be 0.12/100,000 children per year (Henter et al., 1991b). With the more 
widespread availability of genetic testing, it is apparent that the first significant episode of 
HLH can occur throughout life from prenatal presentations through to the seventh decade. 
There is no exact data on the incidence of any form of the acquired HLH. In 2007, a 
retrospective study was published analyzing HLH cases diagnosed in Japan between 2001 
and 2005 (Ishii et al., 2007). The most frequent form of HLH in all age groups in Japan was 
EBV-associated HLH (35%; 163/469 pts), followed by other infection–associated HLH (29%; 
138/469 pts), lymphoma–associated HLH (18%; 84/469 pts), autoimmune–associated HLH 
(11%; 53/496), FHL (4.5%; 20/469 pts) and post-HSCT (hematopoietic stem cell 
transplantation) HLH (2.5%; 11/469 pts). The authors estimated that the annual incidence of 
all types of HLH and in all age groups of Japanese patients was 1 case in 800,000 individuals 
per year (Ishii et al., 2007). However, this number is probably underestimated, due to the 
retrospective nature of the study, certain diagnostic difficulties and overlooking or 
misdiagnosing of some HLH cases. In the same study, the reported 5-year overall survival 
was highest in EBV- or other infection-associated HLH (> 80%) and in autoimmune-
associated HLH (almost 90%), intermediate in FHL or B-cell lymphoma-associated HLH 
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(50%), and lowest in T/NK-cell lymphoma-associated HLH (< 15%) (Ishii et al., 2007). A recent 
retrospective population-based study revealed the annual incidence of M-HLH in adults to be 
1:280,000 per year or 0.36/100,000 individuals per year (Machaczka et al., 2011a). The results of 
this study were limited by the small population of the Swedish region of northern Halland, but 
the long observation period of over 14 years strengthened these findings. 
 
 
 
 
 
HLH – hemophagocytic lymphohistiocytosis; EBV – Epstein-Barr virus; CMV – cytomegalovirus; HSV – 
herpes simplex virus; ND – not determined; sJIA – systemic onset juvenile idiopathic arthritis; NHL – 
non-Hodgkin lymphoma; MDS – myelodysplastic syndromes; AML – acute myeloid leukemia; ALL – 
acute lymphoblastic leukemia; MM – multiple myeloma; SCT – stem cell transplantation. 
Table 1. The contemporary classification of different HLH forms 
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The reported incidence of juvenile idiopathic arthritis (JIA) varies from 1 to 22 cases per 
100,000 children, with a prevalence of 8 to 150 cases per 100,000 children (Cassidy & Petty, 
2005; Weiss & Ilowite, 2007). Of these, approximately 10% of patients have the systemic 
form of the disease (i.e., sJIA). It is estimated that approximately 7–10% of patients with sJIA 
develop life-threatening MAS (Janka, 2009; Sawhney et al., 2001), which may occur at any 
time during the course of the disease, with a mortality between 10–20%. Moreover, two 
studies suggested that a mild, subclinical form of MAS may be present in as many as 25–
30% patients with sJIA (Bleesing et al., 2007, Behrens et al., 2007). Although there are also 
numerous reports of MAS in adult onset Still’s disease, SLE, and Kawasaki disease, the 
incidence of MAS in these entities is unknown. However, in considering MAS in general, the 
mortality rate is presumably about 8–22% (Gupta & Weitzman, 2010). 
5. Clinical and laboratory features of HLH and AAHS/MAS 
The most typical signs of HLH are fever (duration ≥7 days, with peaks ≥38.5ºC) and 
splenomegaly associated with pancytopenia (affecting ≥2 cell lineages in peripheral blood), 
cerebromeningeal symptoms, skin rash, lymph node enlargement, jaundice and edema 
(Henter et al., 1991b; Kumakura, 2005; Öst et al., 1998; Reiner & Spivak, 1988). Laboratory 
findings include hyperferritinemia, hypertriglyceridemia, hypofibrinogenemia, 
coagulopathy, liver function abnormalities (i.e., elevated transaminases and bilirubin), 
hypoproteinemia, and hyponatremia (Henter et al., 1991b, 1998, 2007; Janka et al., 1998). 
Histopathological examination reveals accumulation of lymphocytes and histiocytes 
(macrophages), sometimes with hemophagocytic activity, observed in the spleen, bone 
marrow, liver, lymph nodes and cerebrospinal fluid (Henter & Nennesmo, 1997; Henter et 
al., 2007; Janka, 2009; Öst et al., 1998). The histological picture of liver biopsy resembles 
chronic persistent hepatitis (Henter et al., 2007).  In the brain the leptomeninges and 
perivascular spaces are involved (Akima & Sumi, 1984; Henter & Nennesmo, 1997). Other 
typical findings in HLH are low natural killer (NK) cell activity and high levels of the alpha 
chain of the soluble interleukin-2 receptor (sIL-2R, also named sCD25) in serum and CSF 
(Henter et al., 2007; Janka, 2009). Soluble IL-2R (together with an elevated level of ferritin) is 
a marker of generalized inflammation, but very high levels of sIL-2R are almost never seen 
outside of HLH (Filipovich, 2009). Normal ranges of sIL-2R vary with age being highest in 
infants, and lower in teenagers and adults. All the key clinical and laboratory features of 
HLH can be explained by hypercytokinemia and organ infiltration as shown in Table 2 
(Janka, 2009). 
Another important marker of HLH is soluble CD163 (sCD163). The macrophage hemoglobin 
scavenger receptor CD163 is restricted in its expression exclusively to cells of the monocyte–
macrophage lineage (Schaer et al., 2005). The extracellular part of the protein is shed into 
plasma (sCD163), because of proteolytic cleavage upon macrophage activation. Thus, 
sCD163 is a reliable clinical marker of disorders associated with overwhelming macrophage 
activity (Filipovich, 2009; Grom & Mellins, 2010; Schaer et al., 2005). Because sIL-2R and 
sCD163 are soluble molecules shed from the surfaces of activated T cells and macrophages, 
respectively, their levels are likely to increase in the serum regardless of the tissue 
localization of these cells (Grom & Mellins, 2010).  
AAHS/MAS may exhibit all of the characteristic features of HLH. Coagulopathy and 
cardiac impairment are common (Janka, 2009). Neurological symptoms in MAS may 
progress to a severe encephalopathy and coma. Of note, not all patients with  
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HLH symptom/sign Causative factors 
Fever IL-1; IL-6, TNF-ǂ 
Cytopenia in peripheral blood 
suppressive acitivity of TNF-ǂ, INF-Ǆ, and 
the heavy unit of ferritin on hematopoiesis; 
hemophagocytosis 
High concentration of triglycerides in 
blood 
supressive action of increased levels of 
TNF-ǂ on lipoprotein lipase   
Low concentration of fibrinogen in blood 
high levels of plasminogen activator 
secreted by macrophages stimulate 
plasmine and in consequence lead to 
hiperfibrynolisis 
High concentration of ferritin in serum released by activated histiocytes/macrophages 
High concentration of the ǂ chain of the 
sIL-2R in blood secreted by activated T lymphocytes 
Hepatosplenomegaly 
organ infiltrations with activated 
lymphocytes and histiocytes/macrophages  
Increased liver transaminases and 
bilirubin in blood 
Neurological abnormalities 
HLH – hemophagocytic lymphohistiocytosis; IL – interleukin; TNF – tumor necrosis factor; sIL-2R – 
soluble IL-2 receptor (also named sCD25). 
Table 2. Signs and symptoms of HLH and their causes 
autoimmune/autoinflamatory diseases and MAS fulfill at the beginning diagnostic criteria 
for HLH (Janka, 2009). In patients, who already have signs of inflammation such as high 
leukocytosis, elevated platelet count, and elevated levels of fibrinogen, a decline in these 
parameters, without reaching pathological values, may herald MAS (Ravelli et al., 2005). 
MAS as a first symptom of sJIA may be indistinguishable from other cases of HLH when 
arthritis is missing. A high interleukin-1ǃ concentration in blood may also suggest MAS 
rather than classic HLH (Janka, 2009; Henter et al., 1996). Although mild elevation of sIL-2R 
has been reported in many rheumatic diseases including JIA and SLE, a several-fold increase 
in the levels of sIL-2R in these diseases is highly suggestive of MAS (Grom & Mellins, 2010). 
Importantly, other clinical entities associated with high levels of sIL-2R include 
malignancies and some viral infections, such as viral hepatitis, and so these conditions 
should be considered in the differential diagnosis. Nevertheless, sIL-2R receptor and 
sCD163 are now increasingly recognized as important biomarkers of AAHS/MAS 
(Filipovich, 2009; Grom & Mellins, 2010). 
6. Diagnosis of HLH and AAHS/MAS 
In 1991 the HLH Study Group of the Histiocyte Society published the first diagnostic 
guidelines for HLH which were later updated in 2004 (Henter et al., 1991c, 2007). According 
to the current guidelines (HLH-2004), five of the following eight criteria must be fulfilled for 
the diagnosis of HLH: (1) fever, (2) splenomegaly, (3) cytopenias affecting two or three 
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lineages (Hb <90 g/l; PLT <100 × 109/l; neutrophils <1.0 × 109/l), (4) hypertriglyceridemia 
(fasting triglycerides >3.0 mmol/l) and/or hypofibrinogenemia (<1.5 g/l), (5) 
hemophagocytosis in bone marrow, spleen, or lymph nodes, (6) hyperferritinemia (>500 
µg/l), (7) low or absent NK-cell activity, (8) elevated level of sIL-2R (sCD25) >2400 U/ml. 
The last three HLH criteria were introduced in the revised diagnostic guidelines for HLH in 
2004 (Henter et al., 2007). 
There are no validated diagnostic criteria addressed exclusively for AAHS/MAS, and early 
diagnosis is often difficult (Filipovich et al., 2010; Fukaya et al., 2008; Grom & Mellins, 2010). 
In general, in a patient with persistently active underlying rheumatologic disease, a fall in 
the ESR and platelet count, particularly in combination with persistently high CRP and 
increasing levels of serum D-dimer and ferritin, should raise a suspicion of impeding MAS 
(Grom & Mellins, 2010). According to Janka, a C-reactive protein >100 mg/l, increased 
granulopoiesis with left shift in the bone marrow and peripheral blood, and s-ferritin 
concentration >10,000 μg/L (if EBV infection has been excluded) are features strongly 
suggestive of MAS (Janka, 2009). The diagnosis of MAS is usually confirmed by 
demonstration of hemophagocytosis in the bone marrow, liver, lymph nodes, etc. However, 
false negative results may occur owing to sampling errors, particularly at the early stages of 
the syndrome (Grom & Mellins, 2010; Janka 2009). In some patients, subsequent biopsies 
may reveal hemophagocytic macrophages. In patients with negative bone marrow biopsies, 
assessment of the levels of sIL-2R and sCD163 in serum may help with the timely diagnosis 
of MAS (Grom & Mellins, 2010; Komp et al., 1989; Schaer et al., 2005). 
In particular, application of the HLH diagnostic criteria to sJIA patients with suspected MAS 
is problematic. Some of the HLH markers such as lymphadenopathy, splenomegaly, and 
hyperferritinemia are common features of active sJIA itself and therefore do not distinguish 
MAS from a conventional systemic JIA flare (Davi et al., 2011; Grom & Mellins, 2010). Other 
HLH criteria, such as cytopenias and hypofibrinogenemia, become evident only at the late 
stages. This is related to the fact that sJIA patients often have increased white blood cell and 
platelet counts and elevated s-fibrinogen as a part of the inflammatory response in sJIA. 
Therefore, when they develop MAS, they demonstrate cytopenias and hypofibrinogenemia 
to the extent seen in HLH only at the later stage of MAS, when its management becomes 
challenging (Davi et al., 2011; Grom & Mellins, 2010). Diagnosis of MAS is even more 
problematic in SLE patients with autoimmune cytopenias, which are difficult to distinguish 
from cytopenias caused by MAS (Carvalheiras et al., 2010; Grom & Mellins, 2010; Parodi et 
al., 2009). In these patients, the presence of extreme hyperferritinemia and elevated LDH 
should raise suspicion of MAS (Parodi et al., 2009). Attempts to modify the HLH criteria to 
increase their sensitivity and specificity for the diagnosis of MAS in rheumatic conditions 
have been initiated and continue today (Ravelli et al., 2005; Davi et al., 2011). 
7. Case presentations 
Here we present three illustrative cases of patients with different autoimmune diseases 
developing severe AAHS/MAS in the course of their autoimmune disorder. 
7.1 MAS complicating juvenile arthritis and ankylosing spondylitis 
A 31-year-old male was referred from community hospital to the University Hospital (The 
Second Chair of Internal Medicine, Collegium Medicum, Jagiellonian University, Krakow, 
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Poland) because of persistent fever and progressive haemostatic abnormalities (skin bruises, 
undetectable fibrinogen level, prolonged aPTT and INR, markedly elevated FDP and D-
dimer levels). The patient was admitted to a community hospital 3 weeks earlier with signs 
of a possible upper respiratory tract infection (fever, dry cough, sore throat) accompanied by 
herpes labialis. Broad spectrum antibiotic and acyclovir treatment were both ineffective. 
Because of a progressing bi-cytopenia (thrombocytopenia with neutropenia; Fig. 1) a fine 
needle bone marrow biopsy was performed showing no signs of significant primary bone 
marrow suppression.  
Past medical history revealed that the patient suffered from a polyarticular seropositive 
juvenile arthritis since the age of 8 years. In the following years the patient was hospitalized 
several times because of disease exacerbations. Non-steroidal inflammatory drugs, gold 
salts, azathioprine, methotrexate and systemic corticosteroids together with physiotherapy 
were administered at various time periods; synoviectomy was performed twice. At the age 
of 29 a diagnosis of ankylosing spondylitis was established (sacroilitis, presence of HLA-
B27). Approximately 5 months before admission to our Center the patient’s 
immunosuppressive treatment was modified because of poor disease control, and he 
received a TNF-ǂ inhibitor (adalimumab) with good clinical response. 
On admission the patient complained of pain localized to the right subcostal region and 
persistent fever. On physical examination body temperature was 39.2°C, and slight 
hepatomegaly and skin ecchymoses with mucosal bleeding were present. Selected 
laboratory results and hematologic parameters at admission are shown in Table 3. 
Differential diagnosis included DIC with sepsis (blood cultures later showed negative 
results), neutropenic fever (neutrophils 0.29 × 109/l), and opportunistic infections (HBV, 
HCV, EBV, CMV, and HIV infection were excluded). Adalimumab side effects were also 
taken into consideration. Filgrastim, ganciclovir and intravenous gammaglobulins were 
instituted with no improvement. Concomitant medications included ceftazidime, 
vancomycin, amikacin, sulfamethoxazole/trimethoprim, linezolide, tranexamic acid, fresh 
frozen plasma and cryoprecipitate. 
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Fig. 1. Changes in neutrophils and lymphocyte counts before the admission 
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Hematological parameters Reference range Patient’s result 
Hemoglobin g/l 120–170 99 
White blood cells × 109/l 4.0–10 1.0 
Lymphocytes % 20–40 64 
Neutrophils % 58–66 29 
Platelets × 109/l 150–400 90 
Reticulocytes ‰ 3–15 2 
Biochemistry   
AspAT U/l 17–59 263 
AlAT U/l 21–72 116 
LDH U/l 313–618 7,700 
CRP mg/l <5 56.1 
Coagulation tests   
INR  0.85–1.15 1.30 
aPTT sec 25–31.5 55.60 
Fibrinogen g/l 1.8–3.5 undetectable 
Fibrinogen (nephelometry) g/l 1.8–3.5 0.7 
Trombin time sec 14–21 60.1 
D-dimer ng/ml <500 >10,000 
Factor II % 70–120 45.9 
Factor V % 70–120 106.5 
Factor VII % 70–120 109.7 
Factor VIII % 50–120 39.8 
Factor IX % 70–120 94.6 
Factor X % 70–120 76.2 
Factor XI % 70–120 110.9 
Factor XII % 70–120 81.5 
Table 3. The patient’s laboratory results on admission 
Because of a rapidly progressive thrombocytopenia and neutropenia, bone marrow biopsy 
was reinterpreted towards a diagnosis of hemophagocytic syndrome. Multiple macrophages 
(10–15% of nucleated bone marrow cells) together with several hemophagocytes were found 
(Fig. 2).  
A diagnosis of macrophage activation syndrome complicating recent adalimumab treatment 
was established. Six days after the patient’s admission, treatment with etoposide, 
dexamethasone, and cyclosporine A was instituted as recommended by the modified HLH-
2004 protocol (Fig. 3). Body temperature normalized at day 3 of therapy. Etoposide-related 
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nadir occurred at day 20 (platelets 14 × 109/l; leukocytes 0.42 × 109/l) (Table 4). One dose of 
etoposide was omitted and filgrastim (G-CSF) was administered (48 mln units b.i.d) with a 
beneficial effect. Etoposide was then continued for the next 9 months. 
 
 
Fig. 2. Bone marrow aspirate smears showing the centrally placed macrophage laden with 
erythroblasts. Normally developed myeloid cells are present nearby. Wright’s stain, lower 
(× 400) and higher (× 1000) magnification 
 
 
Fig. 3. The patient’s treatment scheme with a HLH-2004 protocol 
Control examination of bone marrow with a fine needle biopsy performed at week 40 of 
treatment confirmed the disappearance of activated macrophages. The patient felt well and 
continues treatment with cyclosporine and low-dose corticosteroids.  
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Parameter (units) 
Baseline 
(nadir/zenith) 
After treatment 
Fever (°C) 39.2 35.8 
Splenomegaly slight - 
Hepatomegaly + - 
Hemoglobin (g/l) 85 137 
Platelets (× 109/l) 14 260 
Neutrophils (× 109/l) 0.29 5.3 
Triglycerides (mmol/l) 6.5 2.84 
Fibrinogen (g/l) undetectable 4.8 
Ferritin (µg/l) >20,000 233.2 
AlAT (U/l) 116 25 
Bilirubin (mol/l) 19 15 
LDH (U/l) 7,687 624 
Hemophagocytosis + - 
Table 4. Changes in selected laboratory and clinical parameters characteristic for MAS 
during the applied therapy (HLH-2004) 
7.2 MAS complicating rheumatoid arthritis 
A 58-years-old patient, suffering from rheumatoid arthritis for 12 years, about 13 months 
after a course of TNF-ǂ inhibitor (etanercept) treatment was admitted to hospital in 
another country due to progressive weakness, weight loss, intensive ankle joint pain and 
fever reaching 40°C. RA flare and infection were excluded and etanercept-related bone 
marrow dysfunction was suspected due to agranulocytosis, leukopenia, and 
thrombocytopenia. The patient had decided to leave the hospital and sought consultation 
in our University Hospital (The Second Chair of Internal Medicine, Collegium Medicum 
of the Jagiellonian University, Krakow, Poland). On admission his general condition was 
satisfactory; physical examination having revealed livedo reticularis on the lower limbs, 
swelling and redness of the left ankle joint, slight splenomegaly and caries of teeth 11 and 
24. The most important laboratory abnormalities are shown in Table 5. Rheumatoid 
arthritis with Felty syndrome was diagnosed 12 years ago based on the presence of 5 ACR 
criteria, positive rheumatoid factor (RF) and elevated anti-cyclic citrullinated peptide 
antibodies (anti-CCP). About a year ago etanercept was started due to the ineffectiveness 
of corticosteroids and methotrexate.  
After admission the patient received three injections of filgrastim (48 mln. units each) and 
antimicrobial treatment was implemented (ceftazidim, amikacin, fluconazole). Teeth 11 and 
24 were extracted. The patient was seen by a hematologist and a fine needle bone marrow 
biopsy was performed showing numerous, typical hemophagocytes (Figure 4). 
A macrophage activation syndrome associated with rheumatic disease (RA) was diagnosed. 
On day 8 of hospitalization, dexamethasone (20 mg qd) and cyclosporine A (dose adjusted 
to trough blood levels) were initiated. Treatment led to a quick decrease in body 
temperature and little later to normalization of the peripheral blood picture (Table 6). 
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Hematological parameters Reference range 
Patient’s 
result 
Hemoglobin g/l 120–170 108 
White blood cells × 109/l 4.0–10 0.62 
Lymphocytes % 20–40 80 
Neutrophils % 58–66 13 
Platelets × 109/l 150–400 56 
Reticulocytes ‰ 3–15 43 
Biochemistry   
AspAT U/l 21–72 16 
AlAT U/l 21–72 11 
Bilirubin mol/l 3–22 12 
LDH U/l 313–618 420 
CRP mg/l <5 54.3 
Coagulation tests   
INR  0.85–1.15 1.08 
aPTT sec 25–31.5 31 
Fibrinogen g/l 1.8–3.5 1.5 
Table 5. The patient’s laboratory results on admission to the University Hospital 
 
Parameter (units) 
Baseline 
(nadir/zenith) 
After treatment 
Fever (°C) 37.2 36.6 
Splenomegaly + - 
Hepatomegaly - - 
Hemoglobin (g/l) 108 133 
Platelets (× 109/l) 25.2 173 
Neutrophils (× 109/l) 0.6 3.43 
Triglycerides (mmol/l) 2.83 2.7 
Fibrinogen (g/l) 1.40 5.2 
Ferritin (µg/l) 1,855 717.5 
AlAT (U/l) 16 52 
Bilirubin (mol/l) 12 not determined 
LDH (U/l) 420 not determined 
Hemophagocytosis + not determined 
Table 6. Changes of selected laboratory and clinical parameters of MAS during the treatment 
with modified HLH-2004 protocol 
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Fig. 4. Bone marrow aspirate smears. The centrally located macrophage shows phagocytosis 
of erythrocytes, erythroblasts and myeloid cells. Wright’s stain, lower (× 400) and higher (× 
1000) magnification 
7.3 MAS complicating systemic lupus erythematosus 
A 46-year-old man was admitted to the University Hospital (The Second Chair of Internal 
Medicine, Collegium Medicum of the Jagiellonian University, Krakow, Poland) in 2010 
because of persistent fever and pulmonary nodules and consolidations. He has been treated 
for the last 10 years for systemic lupus erythematosus (SLE) with renal involvement. His 
SLE was diagnosed in 1991 based on the presence of several ARA criteria (fever, arthralgias, 
pleuritis and pericarditis, proteinuria, anemia, and the presence of ANA in high titer as well 
as ds-DNA antibodies) and typical results of renal biopsy. His medical history revealed 
arterial hypertension, peripherial artery occlusive disease and deep vein thrombosis of both 
lower limbs. Initially SLE was treated with corticosteroids and oral cyclophosphamide, then 
treatment was frequently modified according to the disease activity (azathioprine, 
cyclosporine A, mycophenolate mofetil and plasmapheresis). 
 
Hematological parameters Reference range Patient’s result 
Hemoglobin g/l 120–150 134 
White blood cells × 109/l 4.0–10 9.0 
Lymphocytes % 20–40 12.2 
Neutrophils % 58–66 83.0 
Platelets × 109/l 150–400 57 
Reticulocytes ‰ 3–15 10 
Biochemistry   
AspAT U/l 21–72 38 
AlAT U/L 21–72 50 
Bilirubin mol/l 3–22 11 
LDH U/l 313–618 1,114 
CRP mg/l <5 75.7 
Coagulation tests   
INR  0.85–1.15 0.94 
aPTT sec 25–31.5 25.9 
Fibrinogen g/l 1.8–3.5 5.0 
Table 7. The patient’s laboratory results on admission to the University Hospital 
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The patient’s general condition on admission was satisfactory. His body temperature was 
38.4°C, physical examination revealed neither hepatosplenomegaly nor lymphadenopathy. 
Selected laboratory results and hematologic parameters on admission are shown in Table 7. 
Microbial analysis of bronchoalveolar lavage obtained at bronchoscopy revealed a group I 
Mycobacteria-other-than-tuberculosis (MOTT). Targeted therapy was instituted (rifampicin 
450 mg qd, isoniazide 250 mg qd, ethambutol 750 mg qd and clarithromycin 1000 mg bid) 
with no effect on the fever. Because of the persistent fever, bronchoscopy was repeated one 
month later, but MOTT’s were no longer detectable. Due to the progressive anemia and 
thrombocytopenia a fine needle bone marrow biopsy was performed showing typical 
hemophagocytes, with some of these forming cell conglomerates (Fig. 5). 
 
 
Fig. 5. Wright’s stain of bone marrow aspirate smears. The centrally placed large cell 
conglomerate consists of activated macrophages presenting hemophagocytosis of 
erythroblasts and myeloid cells. Lower (× 200) and higher (× 400) magnification 
 
Parameter (units) 
Reference 
range 
Baseline 
(nadir/zenith) 
After treatment 
Fever (°C)  40.0 36.5 
Splenomegaly  - - 
Hepatomegaly  - - 
Hemoglobin (g/l) 120–170 85 153 
Platelets (× 109/l) 150–400 42.2 118.2 
Neutrophils (× 109/l )  6,100 3,500 
Triglycerides (mmol/l) 0.3–2.26 2.63 1.07 
Fibrinogen (g/l) 1.8–3.5 3.60 3.1 
Ferritin (µg/l) 13–400 1,387 105 
AlAT (U/L) 21–72 142 57 
Bilirubin (mol/l) 3–22 12 11 
LDH (U/L) 313–618 804 452 
Hemophagocytosis  ++ single cells 
Table 8. Changes of selected laboratory and clinical parameters typical for MAS during 
treatment (HLH-2004) 
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Macrophage activation syndrome was diagnosed and one month after the patient’s 
admission treatment with dexamethasone, cyclosporine A, and etoposide was started 
resulting in the normalization of body temperature and peripherial blood morphology. 
Etoposide-related nadir occurred at day 14 (platelets 18 × 109/l, leukocytes 1.0 × 109/l). Two 
etoposide doses were omitted and filgrastim was administered twice (48 mln units qd). 
Intravenous pulses of etoposide were given for the next 2 months, followed by oral 
administration. A control bone marrow examination performed on week 40 of treatment 
showed disappearance of activated macrophages. The patient has continued treatment with 
cyclosporine A in combination with low-dose corticosteroids with continuous improvement 
of his clinical and laboratory parameters (Table 8). 
8. Pathophysiologic and molecular mechanism of HLH 
Although significant progress in understanding the genetics and pathophysiology of 
primary HLH has been achieved during recent years, the pathogenesis of acquired forms of 
HLH is still not fully understood. An exaggerated immune response is the final common 
pathway of HLH, however, there are multiple roads leading to it (Arceci, 2008; Janka, 2009). 
The immune response is often triggered by different stimulants (e.g., infection) and the 
underlying inherited or acquired immune defect. It has been proposed that the clinical 
presentation of HLH is due to uncontrolled activation of immune cells, macrophages and 
CD8+ T lymphocytes (cytotoxic), leading to a massive release of various mediators of 
inflammation such as TNF-ǂ (tumor necrosis factor ǂ), interleukin(IL)-6, IL-8, IL-10, IL-12, 
IL-18, interferon Ǆ, macrophage inflammatory protein (MIP 1-ǂ), and hematopoietic growth 
factors (e.g., GM-CSF) (Filipovich, 2009; Henter et al., 1991a, 1996, 2007; Janka & Schneider, 
2004; Osugi et al., 1997). IL-10 with its anti-inflammatory properties plays many important 
roles in the regulation of autoimmune inflammatory responses, particularly of systemic 
autoimmune disorders such as HLH/MAS. The role of IL-10 as part of an important 
regulatory mechanism involved in HLH has long been proposed (Behrens et al., 2011; 
Benveniste et al., 2000; Osugi et al., 1997). Recently, the roles of T regulatory cells in HLH 
have also been discussed (Verbsky & Grossman, 2006). Low or absent NK-cell function is 
present in many HLH patients and results in difficulties in termination of the exaggerated 
immune response (Filipovich, 2009; Henter et al., 2007). 
There are two major subtypes of genetic causes of HLH. First are those genetic defects, 
grouped under the term FHL, that present with HLH as the primary and only manifestation 
of disease (Gupta & Weitzman, 2010; Henter et al., 2007). A second group of genetic 
disorders include HLH as only one, although often fatal, manifestation of the disease (Gupta 
& Weitzman, 2010; Janka, 2009). All known genetic abnormalities causing FHL involve 
genes that regulate proteins important in the secretory cytolytic pathway of NK-cells and 
CD8+ T lymphocytes. In 1999, the first FHL-inked locus was discovered on chromosome 
9q21.3–22 in several Pakistani families and was later defined as the FHL1 subtype (Ohadi et 
al., 1999). Shortly thereafter, mutations in the perforin gene PRF1 were discovered on 
chromosome 10q21 in a group of patients with FHL (FHL2 subtype) (Stepp et al., 1999). 
Furthermore, mutations in genes UNC13D (located on chromosome 17q25; FHL3 subtype), 
STX11 (located on chromosome 6q24; FHL4 subtype), and most recently STXBP2 (located on 
chromosome 19p13; FHL5 subtype) were described (Feldmann 2003; zur Stadt et al., 2005, 
2009). In view of the remarkable progress since the discovery of the first genetic defect in 
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FHL in 1999, it is expected that many new mutations in the known genes will be identified, 
as well as some novel gene mutations (Gupta & Weitzman, 2010). 
Viruses, non-steroidal anti-inflammatory drugs, methotrexate, gold salts, and even TNF-ǂ 
inhibitors have been reported as triggers for AAHS/MAS (Gupta & Weitzman, 2010). 
Interestingly, distinctions between genetically determined and acquired HLH become 
increasingly blurred as brand new genetic causes are identified, and patients who develop 
HLH beyond early childhood or in the contexts of EBV infection or autoimmune disease are 
being found to share some of the same genetic etiologies (Arceci, 2008; Hazen et al., 2008; 
Nagafuji et al., 2007; Zhang et al., 2008). Patients who develop sHLH may also have a 
genetic predisposition, but the molecular basis of the defects in sHLH has yet to be 
discovered (Arceci, 2008). This supposition has recently been strengthened by recent studies 
showing decreased NK cell function or reduced perforin expression in children with sJIA 
complicated by MAS, similarly to patients with FHL (Grom et al., 2003; Wulffraat et al., 
2003). Of note, mutations in UNC13D gene, mutated in FHL type 3, were also described in 
patients with sJIA (Hazen et al., 2008; Zhang et al., 2008). 
9. Treatment of HLH and AAHS/MAS 
Early diagnosis and the prompt introduction of adequate therapy to produce a rapid 
response are crucial for a positive outcome in HLH. The treatment of any HLH type should 
focus on: (1) suppression of the hyperinflammatory state by destruction of activated CD8+ T 
lymphocytes and macrophages, and (2) treatment of any existing triggers (Gupta & 
Weitzman, 2010; Henter et al., 2007). In cases of FHL, an additional aim is the correction of 
the underlying immune defect (Filipovich, 2009; Henter et al., 2007; Janka, 2009). HLH 
treatment categories include: (1) proapoptotic chemotherapy with etoposide (100–150 
mg/m²/dose i.v.), and (2) immunosuppressive drugs, targeting the hyperactivated 
macrophages (e.g., etoposide, corticosteroids, intravenous immunoglobulin), and T 
lymphocytes (e.g., corticosteroids, cyclosporine A [CyA]) (Henter et al., 2007). In 1994 the 
first prospective international treatment protocol (HLH-94) was introduced (Henetr et al., 
1997). The experience from the HLH-94 protocol (including etoposide and dexamethasone 
[DXM]) and other studies have led to the development of a new treatment protocol, HLH-
2004 (including etoposide, DXM, CyA) (Henter et al., 2007). However, 
immunochemotherapy (i.e., HLH-94 and HLH-2004 protocols) is only temporarily effective 
in the control of FHL, and the outcome is uniformly fatal unless the patient undergoes 
allogeneic stem cell transplantation (alloSCT) (Jordan & Filipovich, 2008; Henter et al., 2007). 
Last but not least, since patients with HLH represent a unique population with high 
morbidity/mortality and disease-specific complications, consideration should be given to 
referring these patients to centers with significant experience in the treatment and care of 
HLH. 
9.1 Immunochemotherapy 
Initially mild cases of HLH can deteriorate rapidly within a short period of time. Therefore, 
prompt administration of effective HLH therapy may prevent development of the full-
blown syndrome. So far, treatment of AAHS/MAS is not standardized and remains highly 
variable across clinical centers (Deane et al., 2010). Nevertheless, a frontline treatment of 
AAHS/MAS (particularly of milder grades) usually involves corticosteroids with or without 
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intravenous immunoglobulin (IVIG), which may be sufficient to control hyperinflammation 
(Janka, 2009). In order to achieve rapid reversal of the coagulation abnormalities and 
cytopenias, most clinicians prefer starting with intraveneous methylprednisolone pulse 
therapy (30 mg/kg for 3 consecutive days) followed by 2 to 3 mg/kg/day divided by 4 
doses (Filipovich et al., 2010). After improvement of the complete blood count and 
resolution of the coagulopathy, steroids are tapered slowly to avoid relapses of MAS (Janka, 
2009; Filipovich et al., 2010). High-dose corticosteroids alone have been reported to induce 
remission in approximately half of MAS patients (Sawhney et al., 2001 Stephan et al., 2001). 
Administration of IVIG might be effective in AAHS/MAS. High dose IVIG infusions are 
immunosuppressive, in part engaging Fc-receptors, which can play an important role in 
same patients with autoimmune/autoinflammatory diseases (Arceci, 2008; Kumakura et al., 
2004). IVIG may also provide an anti-pathogen effect, which is particularly important if 
MAS is triggered by a viral infection.   
Even when treatment is introduced in a timely manner, MAS can be fatal and deaths have 
been reported among patients treated with massive doses of steroids (Filipovich et al., 2010). 
However, corticosteroid resistant non-responders may benefit from second-line therapies, 
such as CyA or etoposide. Parenteral administration of CyA has been shown to be effective 
in patients with corticosteroid-resistant MAS (Mouy et al., 1996; Ravelli et al., 1996). Of note, 
in author’s experience, some patients with MAS have not responded until etoposide was 
added to the HLH therapy. The similar conclusion has recently been postulated by other 
authors (Gupta & Weitzman, 2010). Thus, if there is no response to the aforementioned 
drugs (corticosteroids, IVIG, CyA), use of the HLH-2004 protocol including etoposide is 
recommended (Table 9). In summary, patients with suspected AAHS/MAS could be started 
on therapy without etoposide, as long as treatment adjustments are made rapidly in 
refractory cases (Gupta & Weitzman, 2010). 
The utility of biological response modifiers in MAS treatment remains unclear, and at the 
present there is no consensus on recommendations in respect to this group of drugs. The use 
of TNF-ǂ inhibitors (etanercept, infliximab) in MAS has produced conflicting results, being 
the effective therapy in some patients (Makay et al., 2008; Sellmer et al., 2011), while 
triggering MAS in others (Sandhu et al., 2007). Biological agents that neutralize IL-1 
(anakinra) and IL-6 (tocilizumab) have been reported to be effective in occasional MAS 
patients (Filipovich et al., 2010; Kelly & Ramanan, 2008), but the clinical experience is as yet 
limited. In the case of patients with a form of sHLH other than AAHS/MAS, which proved 
refractory to frontline HLH therapy, anecdotal reports on the beneficial use of plasma 
exchange, hemofiltration, antithrombin III, anti-CD52 antibodies (alemtuzumab), and anti-
CD25 antibodies (daclizumab) have been published previously, but the role of these 
therapies is not yet validated for any type of HLH (Gupta & Weitzman, 2010). Lastly, if MAS 
is driven by EBV infection, monoclonal anti-CD20 antibodies (rituximab) which deplete B 
lymphocytes, the main type of cells harboring EBV virus, should be used (Balamuth et al., 
2007). 
9.2 Stem cell transplantation 
The first successful allogeneic bone marrow transplantation in a case of HLH was reported 
in 1986 (Fischer et al., 1986). Since then, information regarding the role of alloSCT in the 
treatment of HLH has mostly concerned FHL (Janka, 2009; Marsh et al., 2010). In FHL, 
alloSCT is the only available curative treatment option with the reported 5-year overall 
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 Children Adults* 
Initial therapy 
(weeks 1–8) 
aiming remission 
of HLH 
Etoposide
150 mg/m² i.v. 
twice weekly in 2 weeks followed 
by once weekly administration 
(week 3–8)
50–120 mg/m² i.v. 
twice weekly in 2 weeks followed 
by once weekly administration 
(week 3–8)
Caution! Adults usually do not tolerate as high etoposide doses as 
children, therefore dose reduction is indicated as proposed above 
Dexamethasone
10 mg/m² p.o. daily in 2 weeks (week 1–2)
5 mg/m² p.o. daily in 2 weeks (week 3–4) 
2.5 mg/m² p.o. daily in 2 weeks (week 5–6) 
1.25 mg/m² p.o. daily in 1 week (week 7) 
tapering and discontinuation during week 8
Cyclosporine A
3 mg/kg p.o. twice daily during the first week of therapy, followed 
by dose aiming CyA concentration at trough of 200 µg/l (week 2–8) 
Caution! Adults usually do not tolerate as high CyA concentrations as 
children, and CyA concentrations of 100–200 µg/l may be acceptable 
General remarks:
1. Maximal initial supportive care is suggested, inclusive: 
appropriate broad-spectrum antibiotics (until culture results); 
prophylactic co-trimoxazole (equivalent to 5 mg/kg of 
trimethoprim 3 times weekly); an oral antimycotic therapy; 
antiviral therapy in patients with ongoing viral infection; and 
IVIG (0.5 g/kg) once every 4 weeks 
2. Gastroprotection due to the high steroids doses is recommended 
(e.g., PPIs) 
3. If after 2 weeks there is clinical evidence of progressive 
neurological symptoms or if abnormal CSF (pleocytosis and 
elevated proteins) has not improved, 4 weekly intrathecal 
Methotrexate injections are recommended
Continuation 
therapy (≥ week 9) 
after achieved 
HLH remission 
until alloSCT or 
therapy 
discontinuation 
Etoposide
150 mg/m² i.v.
once weekly every alternating 
(with Dexamethasone) second 
week
50–100 mg/m² i.v.
once weekly every alternating 
(with Dexamethasone) second 
week
Dexamethasone
pulses of 10 mg/m² p.o. for 3 consecutive days, given every 
alternating (with etoposide) second week
Cyclosporine A
dose aiming CyA concentration at trough of 200 µg/l (adults 100–200 µg/l) 
* – etoposide dose recommendations for adults are not validated proposal, but based on clinical 
experience (personal communication with Jan-Inge Henter) 
HLH - hemophagocytic lymphohistiocytosis; CSF – cerebrospinal fluid; CyA – cyclosporine A; IVIG - 
intravenous immunoglobulin; PPI – proton pump inhibitor. 
Table 9. The HLH-2004 immunochemotherapy protocol for management of hemophagocytic 
lymphohistiocytosis 
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survival rate of 50–70% with myeloablative conditioning (MAC) (Baker et al., 1997; Cesaro et 
al., 2008; Dürken et al., 1999; Horne et al., 2005; Imashuku et al., 1999; Jabado et al., 1997; 
Ouachèe-Chardin et al., 2006), and 75–92% with reduced-intensity conditioning (RIC) 
(Cooper et al., 2006; Marsh et al., 2010). 
So far, alloSCT has been performed only occasionally in cases of acquired HLH and its role 
in the treatment of sHLH is not yet established. Sporadic case reports have previously been 
published on refractory EBV-HLH successfully treated by means of alloSCT (Minegishi et 
al., 2001; Sovinz et al., 2010; Toubo et al., 2004). A recent Japanese survey revealed a curative 
effect of alloSCT on sHLH in 7 out of 11 patients (64%) with refractory EBV-HLH (Ogha et 
al., 2010). Similarly, Yoon et al. reported that alloSCT could be a curative treatment not only 
for FHL, but also for relapsed/refractory sHLH (Yoon et al., 2010). Anecdotal reports have 
also shown the efficacy of alloSCT in M-HLH therapy (Chang et al., 2009; Goi et al., 1999; 
Kelly et al., 2011; Machaczka et al., 2011b). 
No concerted effort to apply alloSCT for the definitive treatment of MAS has yet been made. 
Given the high mortality associated with the current management of AAHS/MAS, the 
option of alloSCT using less intensive conditioning protocols, is reasonable to consider, 
especially in cases of severe or recurrent MAS episodes (Filipovich et al., 2010). Of note, 
sometimes fatal MAS was observed as a complication of prolonged T lymphocyte 
immunodeficiency in early trials of autologous stem cell transplantation for severe 
progressive systemic or polyarticular juvenile idiopathic arthritis (Filipovich et al., 2010). 
These observations suggested a failure to control the underlying disease given the patient’s 
genetically predisposed hematopoietic stem cells (Bleesing et al., 2007). 
10. Conclusions 
Autoimmune-associated hemophagocytic syndrome/macrophage activation syndrome is 
a life-threatening hyperinflammatory syndrome which remains a major cause of 
morbidity and mortality in patients with autoimmune/autoinflammatory diseases. 
Awareness of AAHS/MAS, its symptoms and diagnostic criteria should be made 
mandatory among all physicians, especially those providing care to patients with 
autoimmune/autoinflammatory diseases. There are no validated diagnostic criteria 
making early MAS diagnosis difficult in part owing to strong similarities between MAS 
and sepsis. The treatment of MAS remains highly variable across clinical centers. 
Nevertheless, the frontline treatment of AAHS/MAS usually involves corticosteroids with 
or without intravenous immunoglobulin. In some patients with corticosteroid-refractory 
MAS, administration of cyclosporine A circumvents refractoriness. If there is no response 
to the aforementioned treatments a use of etoposide is recommended. The progress in 
understanding the pathophysiology behind MAS and identification of the pathways 
associated with the early stages of this syndrome bring hope to the idea of developing 
new biomarkers and treatments for clinical practice. 
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